EST DexCom (DXCM) falls 7% to $71.99 after receiving warning letter from FDADiscover the Best Stocks and Maximize Your Portfolio: See ...

Of the hundreds of millions of people living with diabetes, most liv. Dexcom wants to make sure they have tools to manage it.

Dexcom was issued with an FDA warning letter after issues with “manufacturing processes and quality management systems.” ...

Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

The announcement came after a quarter where DexCom reported a 7% increase in sales, though net income declined significantly alongside a reduction in earnings per share. During the past quarter ...

The FDA cited issues with DexCom's response to prior inspection findings, known as Form 483 observations. The inspections took place at the San Diego facility between October 21 and November 7 ...

DexCom , Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) systems for diabetes management with a market capitalization of $34.8 billion, finds itself at a critical juncture as ...

reached an agreement with DexCom to settle all outstanding patent disputes related to continuous glucose monitoring products. The agreement will dismiss all pending cases in courts and patent ...

DexCom (NASDAQ:DXCM), known for its continuous ... Conversely, the Non-GAAP operating income dropped 13.7% to $209.5 million, and the Non-GAAP EPS of $0.45 indicated a 10% year-over-year decline ...

DexCom, Inc. (NASDAQ ... the Middle East and North Africa—90-95%6,7 of whom have Type 2 diabetes. “With policymakers increasingly focused on digital transformation in healthcare, now is ...